Replies to post #252148 on Biotech Values

[dewophile]

patients/docs are trying to hide treatment/infections history to get into the trial. Only to be rejected after more thorough background review

HL has one of the best prognosis for cure, but relapsed/refractory HL has one of the worst prognosis (even with checkpoints and adcetris helping some of these patients), so you have a mostly young population that is desperate. Still odd to have this kind of behavior in a clinical trial setting

2 of these patients are now trying Acetris first

Almost every HL pt at this stage has seen Adcetris already. Many now first line, but if not in first line in the relapsed setting. However there is data showing response to retreatment with Adcetris so it can buy some time in some as far as I know